|
|
 |
|
Viewing report
|
|
|
|
Adme/Tox Technologies
RI Technologies, Jan 2008, Pages: 195
This market insight report on ADME/Tox Technologies covers both products and services used in the ADME/TOX industry. Predictive technologies analyzed include In vivo, In vitro, and In silico. Related technologies such as High Throughput Screening (HTS), and cell based assays are also analyzed. Market projections and estimates are illustrated by region and by technology. The report serves as a guide to ADME/Tox industry, covering 341companies that are engaged in ADME/Tox studies/screening, products and services. Major Contract Research Organizations serving ADME/Tox industry are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. A global perspective is presented along with regional analysis covering the regions of North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa with 145 exclusive graphically represented exhibits.
Time and Money - both can be saved by applying ADME/Tox technologies in the early drug discovery processes. ADME/Tox studies determine dosage and toxicity issues for any new drug before human trials. Most of the drugs fail in the clinical development phase due to their poor ADME/Tox properties. Companies are making robust efforts in eliminating poor elements before they enter into clinical trials. Drug failure in or post clinical trial phase may lead the company into economic disasters.
The global ADME/Tox market is projected to reach US$ 4.4 billion by 2012. Asia Pacific and Latin America are the emerging markets for clinical trials after the US, Canada and Europe. Contract Research Organizations (CROs) from across the globe, especially from the US and Europe, are establishing their facilities for clinical trials in these regions. With lot of support from government and numerous collaborations with government institutions and laboratories by industry giants including Becton Dickinson,
GlaxoSmithKline and Corning, Singapore and Hong Kong are emerging as promising markets making Asia-Pacific the fastest growing ADME/Tox market during 2005-2012.
Toxicity profiles of drugs can now be studied very early in developmental stages courtesy the evolving ADME/Tox tools market. The technological improvements have time and again demonstrated that no single drug reacts in the same manner across all demographic profiles of humankind such as the aged population, the middle aged ones, adolescents, and children. Also, human mind conditions are an important criterion as mentally ill people react differently from the normal people. Pathbreaking developments in bioanalytical technology include High Pressure Liquid Chromatography (HPLC), radioimmunoassays, mass spectrometry, and genetic engineering.
Prediction of potential human risks of a new drug candidate is crucial in early stages of the drug discovery/development process. Even 10%-12% increase in identifying failures before a drug candidate entering the clinical trial stage could save the company over US$100 million. Identification of numerous biological pathways and networks that pose potential targets for the treatment of disease is driven by latest technologies for understanding disease’s molecular mechanism and by the completion of Human Genome Project. This phenomenon created hopes for increased number of new molecule entities to obtain approval from regulatory authorities. In fact, most of the candidate drugs are failing at clinical testing phase due to poor pharmacokinetic (ADME) properties, non-efficacy and toxicity.
The pharmaceutical industry is on the cutting edge of change. The industry is constantly under pressure to develop new products for the medical industry and of course also to earn profits. The federal regulatory systems order very high standards for benchmarking successful drugs before final approval. Companies that produce state-of-art tools and focus on complete solutions will be clear winners. Automation is the way to go with emphasis on lower costs. Clearly, animal models cannot be totally overruled owing to traditional concerns, and also the comfort level involved since they provide the closest biological environment to human systems.
Customers who bought this item also bought
Predictive ADME and Toxicology Strategies: Challenges and Opportunities for In Vivo, In Vitro and In Silico Predictive Technologies
Managing Toxicology for the Future: Improving Predictive Power Through Integrated Technologies, 2nd Edition
Strategic Analysis of the ADME/TOX Technologies Market in Europe
U.S. ADME/Tox in Drug Development Markets
ADME in Children and The Elderly: Clinical Challenges and Opportunities
The Impact of 3G & 4G Wireless Technology On Carriers Network Development Strategies
Analyzing the Global Aerospace and Defense Industry
Global Communications Power: Market Forecasts, Business Trends and Competitive Analysis, Eighth Edition
|
|
|
|
